Want to see HK:2291 full AI Analyst Report?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (2291) AI Stock Analysis
Top Page
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
(HKEX:2291)
The score is driven primarily by strong financial quality (high margins and an exceptionally low-leverage balance sheet), supported by a bullish technical trend with moderate momentum. Valuation is fair-to-attractive due to a reasonable P/E and solid dividend yield, partially offset by the 2025 revenue decline and the business’s historical earnings/cash-flow volatility.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (2291) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 4.50B
- Dividend Yield
- 4.35%
- Average Volume (3M)
- 694.77K
- Price to Earnings (P/E)
- 18.9
- Beta (1Y)
- 0.72
- Revenue Growth
- -4.20%
- EPS Growth
- -25.57%
- Country
- Hong Kong
- Employees
- 371
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solu...
How the Company Makes Money
null
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Financial Statement Overview
Summary
High profitability and a very conservative balance sheet underpin a strong financial profile. Key offsets are the 2025 revenue contraction and historical volatility (notably the 2022 net loss and negative free cash flow), though cash flow has improved meaningfully into 2023–2025.
Income Statement
86Very PositiveBalance Sheet
94Very PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 504.09M | 527.94M | 471.64M | 325.90M | 247.67M | 222.58M |
| Gross Profit | 413.55M | 446.95M | 424.03M | 288.81M | 219.69M | 197.54M |
| EBITDA | 252.40M | 286.23M | 307.78M | 189.20M | 18.81M | 87.38M |
| Net Income | 202.22M | 239.73M | 245.56M | 151.53M | -19.81M | 58.70M |
Balance Sheet | ||||||
| Total Assets | 2.24B | 2.10B | 2.08B | 1.99B | 1.81B | 1.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.16B | 1.13B | 1.27B | 1.20B | 713.48M |
| Total Debt | 1.40M | 1.72M | 1.51M | 2.44M | 3.33M | 6.19M |
| Total Liabilities | 240.63M | 61.47M | 85.98M | 59.79M | 65.09M | 734.50M |
| Stockholders Equity | 2.00B | 2.04B | 2.00B | 1.93B | 1.74B | 385.19M |
Cash Flow | ||||||
| Free Cash Flow | 156.58M | 144.66M | 137.05M | 66.75M | -17.83M | 13.44M |
| Operating Cash Flow | 208.56M | 221.10M | 222.49M | 164.26M | 65.53M | 105.28M |
| Investing Cash Flow | -57.17M | 28.73M | -117.22M | 111.32M | -406.00M | -85.17M |
| Financing Cash Flow | -219.88M | -216.55M | -196.91M | -2.05M | 577.80M | 672.23M |
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2291, the sentiment is Neutral. The current price of 13.15 is below the 20-day moving average (MA) of 13.64, above the 50-day MA of 12.76, and above the 200-day MA of 12.67, indicating a neutral trend. The MACD of 0.53 indicates Positive momentum. The RSI at 48.11 is Neutral, neither overbought nor oversold. The STOCH value of 52.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2291.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Peers Comparison
Overall Rating
- HK:229185Outperform
HK:961661Neutral
HK:163157Neutral
HK:158647Neutral
HK:845045Neutral
HK:839139Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2291 | 85Outperform | HKD 4.51B | 18.87 | 10.01% | 4.35% | -4.20% | -25.57% |
| HK:9616 | 61Neutral | HKD 1.09B | 2.31 | 16.37% | 16.52% | 7.27% | 8.34% |
| HK:1631 | 57Neutral | HKD 362.50M | 115.16 | 2.93% | ― | -2.70% | -64.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1586 | 47Neutral | HKD 797.82M | 18.14 | 8.99% | ― | 13.24% | -42.14% |
| HK:8450 | 45Neutral | HKD 620.00M | -31.79 | -58.20% | ― | 46.69% | -24.56% |
| HK:8391 | 39Underperform | HKD 260.30M | -3.32 | 269.90% | ― | -13.98% | 47.47% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2291 | LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H | 13.15 | -5.35 | -28.94% | |
| HK:9616 | Neusoft Education Technology Co. Limited | 1.69 | -0.52 | -23.67% | |
| HK:1586 | China Leon Inspection Holding Limited | 1.36 | -1.52 | -52.78% | |
| HK:1631 | REF Holdings Limited | 1.18 | 0.76 | 180.95% | |
| HK:8391 | Cornerstone Technologies Holdings Limited | 0.25 | -0.41 | -62.42% | |
| HK:8450 | EDICO Holdings Limited | 0.62 | 0.51 | 479.44% |
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Corporate Events
LEPU ScienTech Overhauls Company Secretarial Team, Seeks Listing Rules Waiver
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. has announced changes to its corporate secretarial and compliance structure, with the resignation of joint company secretaries Qin Xue and Yeung Lai Shan due to work adjustments effective Oct. 22...
LEPU ScienTech Delays Circular on Major Shanghai Minwei Acquisition
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., a PRC-incorporated medical technology company listed in Hong Kong, operates as a non-Hong Kong registered issuer under the Companies Ordinance while maintaining its main base in Shanghai. The fi...
LEPU ScienTech Wins Approval for New PFO Occluder, Bolstering Cardiac Device Portfolio
LEPU ScienTech Medical Technology announced that its subsidiary Shanghai Shape Memory Alloy has received a National Medical Products Administration registration certificate for the MemoCarna Oxide Film Single-Rivet Patent Foramen Ovale Occluder. The...
LEPU ScienTech Delays Circular on Major Shanghai Biotech Acquisition
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. has announced a delay in sending a shareholder circular relating to its planned acquisition of a 54.2384 percent equity interest in Shanghai Minwei Biotechnology Co., Ltd. The transaction has bee...
Lepu ScienTech Plans RMB1.09 Billion Connected Acquisition in Biotech Arm
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd., a Hong Kong-listed PRC medical technology group, is expanding its footprint in biotechnology through a large related-party investment. The company’s governance framework requires that modi...
Lepu ScienTech Profit Slides as Cardiovascular Device Maker Tightens Spending
Lepu ScienTech reported that for the six months ended 30 June 2026, revenue fell 5.9% year-on-year to RMB310.1 million and gross profit dropped 10.5% to RMB254.5 million, while net profit attributable to shareholders declined 19.5% to RMB146.5 millio...
LEPU ScienTech Schedules Board Meeting to Review Interim Results and Dividend
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. has scheduled a board meeting for August 21, 2026 to review and approve the interim results for the six months ended June 30, 2026, along with their planned publication. The board will also consi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026